Multi-parameter diabetes risk evaluations
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
Life of this patent
Estimating the term…
Abstract
Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
Claims39
A method of evaluating a subject's risk of developing type 2 diabetes, comprising:
- programmatically calculating a diabetes risk index of a subject using at least one defined mathematical model of risk of developing type 2 diabetes that includes a measurement of at least one lipoprotein component and at least one of a measurement of (i) GlycA or GlycB or (ii) at least one branched chain amino acid, obtained from at least one in vitro biosample of the subject.
5-6. (canceled)
(canceled)
10-13. (canceled)
17-19. (canceled)
21-25. (canceled)
A circuit configured to determine whether a patient is at-risk for developing type 2 diabetes and/or whether a patient has prediabetes, comprising:
- at least one processor configured to electronically calculate a diabetes risk index based on at least one mathematical model of risk to convergence to type 2 diabetes that considers a measurement of at least one lipoprotein component and a measurement of either (i) at least one branched chain amino acid or GlycA or (ii) at least one branched chain amino acid and GlycA, from at least one in vitro biosample of the subject.
(canceled)
32-33. (canceled)
36-40. (canceled)
A computer program product for evaluating in vitro patient biosamples, the computer program product comprising:
- a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
- computer readable program code that provides at least one mathematical model of risk to progression to type 2 diabetes in the future, wherein the at least one mathematical model of risk to progression to type 2 diabetes includes a plurality of components, including at least one lipoprotein component, at least one inflammatory biomarker and at least one branched chain amino acid;
- and
- computer readable program code that calculates a diabetes risk index associated with a patient's biosample based on the at least one mathematical model of a risk of developing type 2 diabetes,
- wherein the defined mathematical model of risk comprises GlycA as the inflammatory biomarker, and wherein the at least one lipoprotein component includes an interaction parameter of a measurement of GlycA multiplied by a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.
43-45. (canceled)
The computer program product of claim 44, wherein the defined HDL subpopulation includes only medium HDL particle subclasses with diameters between 8.3 nm (average) to about 10.0 nm (average).
47-53. (canceled)
A system, comprising:
- an NMR spectrometer for acquiring at least one NMR spectrum of an in vitro biosample;
- and
- at least one processor in communication with the NMR spectrometer, the at least one processor configured to determine, for a respective biosample using the acquired at least one NMR spectrum, a diabetes risk index score based on at least one defined mathematical model of risk to convergence to type 2 diabetes that includes GlycA, at least one interaction parameter comprising GlycA and at least one lipoprotein component, and at least one branched chain amino acid obtained from at least one in vitro biosample of the subject, and wherein the at least one lipoprotein component of the interaction parameter includes a concentration of a defined subpopulation of high density lipoprotein (HDL) particles.
55-70. (canceled)
An NMR system comprising:
- a NMR spectrometer;
- a flow probe in communication with the spectrometer;
- and
- at least one processor in communication with the spectrometer configured to obtain (i) NMR signal of a defined GlycA fitting region of NMR spectra associated with GlycA of a blood plasma or serum specimen in the flow probe;
- (ii) NMR signal of a defined branched chain amino acid fitting region of NMR spectra associated with the specimen in the flow probe;
- and (iii) NMR signal of lipoprotein subclasses;
- wherein the at least one processor is configured to calculate measurements of (i) GlycA, (ii) at least one branched chain amino acid and (iii) the lipoprotein subclasses using the NMR signals, and wherein the at least one processor is configured to calculate a diabetes risk index that uses the calculated measurements of GlycA, the at least one branched chain amino acid and some of the lipoprotein subclasses.
(canceled)
(canceled)
(canceled)
A method of monitoring a patient to evaluate a therapy or to determine whether the patient is at-risk of developing type 2 diabetes, comprising:
- programmatically evaluating a plurality of NMR derived measurements of selected lipoprotein subclasses and at least one of (i) at least one branched chain amino acid or GlycA or (ii) at least one branched chain amino acid and GlycA, of at least one patient in vitro biosample;
- programmatically calculating a diabetes risk index of respective patients using the NMR derived, measurements;
- and
- evaluating at least one of (i) whether the diabetes risk index is above a defined level of a population norm associated with increased risk of developing type 2 diabetes;
- and/or (ii) whether the diabetes risk index is increasing or decreasing over time to thereby evaluate change in risk status that may be in response to a therapy.
Dependencies are inferred from the claim text.